Back to results
US 12,642,859 B2Granted
Macropinocytosis selective monobody-drug conjugates
AssigneeNew York University
InventorsCraig Ramirez, Andrew Hauser, Nathan Beals, Dafna Bar-Sagi, Akiko Koide, Shohei Koide
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to pharmaceutical and diagnostic compositions comprising macropinocytosis selective non-binding protein-drug conjugates. These non-binding protein-drug conjugates comprise a non-binding fibronectin type III (FN3) domain coupled to a pharmaceutically active moiety or a diagnostic moiety. The disclosure is also directed to methods of treatment and diagnosis that involve administering the pharmaceutical compositions described herein to a subject in need.
Claims17
A pharmaceutical composition comprising:
- a non-binding protein-drug conjugate and a pharmaceutically acceptable carrier, wherein said non-binding protein-drug conjugate comprises:
- [i] a first portion, said first portion comprising a non-binding human fibronectin type III (FN3) domain, wherein the non-binding FN3 domain comprises the amino acid sequence of SEQ ID NO:
- 2 or SEQ ID NO:
- 3, and wherein the amino acid sequence of SEQ ID NO:
- 2 does not comprise SEQ ID NO:
- 1;
- [ii] an amino acid linker within or coupled to the first portion;
- and
- [iii] a second portion coupled to said first portion via the amino acid linker, said second portion selected from a pharmaceutically active moiety or a diagnostic moiety.
6 more elements
Dependencies are inferred from the claim text.